While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Ivim takes a comprehensive approach to obesity care and its customized patient-centric plans are carefully overseen by ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food.

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...